natgillin/translations-raw huggingface dataset:
The mean absolute oral bioavailability is 15%.
Povprečna absolutna biološka uporabnost je 15- odstotna.
When vardenafil is taken with a high fat meal (containing 57% fat), the rate of absorption is reduced, with an increase in the median tmax of 1 hour and a mean reduction in Cmax of 20%.
Če se vardenafil zaužije skupaj s hrano, ki vsebuje veliko maščob (57% maščob), se zmanjša stopnja absorpcije, srednja vrednost tmax se zveča za 1 uro in Cmax zmanjša povprečno za 20%.
After a meal containing 30% fat, the rate and extent of absorption of vardenafil (tmax, Cmax and AUC) are unchanged compared to administration under fasting conditions.
Če hrana vsebuje 30% maščob, se stopnja in obseg absorpcije vardenafila (tmax, Cmax in AUC) v primerjavi z jemanjem na tešče ne spremenita.
Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins (approximately 95% for vardenafil or M1).
Vardenafil in njegovi glavni presnovek (M1) v obtoku se obsežno vežeta na plazemske beljakovine (približno 95% vardenafila ali M1).
Based on measurements of vardenafil in semen of healthy subjects 90 minutes after dosing, not more than 0.00012% of the administered dose may appear in the semen of patients.
Meritve vardenafila v semenu zdravih preiskovancev 90 minut po odmerjanju kažejo, da se v semenu bolnikov ne more pojaviti več kot 0, 00012% zaužitega odmerka.
Vardenafil is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
Vardenafil se presnavlja predvsem v jetrih s pomočjo citokroma P450 (CYP), izooblike 3A4, pri čemer nekoliko prispevata tudi izoobliki CYP3A5 in CYP2C.
In humans the one major circulating metabolite (M1) results from desethylation of vardenafil and is subject to further metabolism with a plasma elimination half life of approximately 4 hours.
Razpolovna doba izločanja iz plazme traja približno 4 ure.
Parts of M1 are in the form of the glucuronide in systemic circulation.
Deli M1 so v obliki glukuronida v sistemskem obtoku.
Metabolite M1 shows a phosphodiesterase selectivity profile similar to vardenafil and an in vitro potency for phosphodiesterase type 5 of approximately 28% compared to vardenafil, resulting in an efficacy contribution of about 7%.
Presnovek M1 je selektiven za fosfodiesteraze podobno kot vardenafil, in vitro pa je afiniteta za fosfodiesterazo tipa 5 v primerjavi z vardenafilom 28- odstotna, kar pomeni, da je njegov prispevek k učinkovitosti 7- odstoten.
The total body clearance of vardenafil is 56 l/ h with a resultant terminal half life of approximately 4-5 hours.
Celoten očistek vardenafila iz telesa znaša 56 l/ h.
After oral administration, vardenafil is excreted as metabolites predominantly in the faeces (approximately 91-95% of the administered dose) and to a lesser extent in the urine (approximately 2-6% of the administered dose).
Po peroralnem zaužitju se vardenafil v obliki presnovkov izloča pretežno z blatom (približno 91 do 95% zaužitega odmerka) in v manjši meri tudi s sečem (približno 2 do 6% odmerka).
Elderly Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced as compared to healthy younger volunteers (18 - 45 years).
Starostniki Pri zdravih starejših prostovoljcih (starih 65 let in več) se je izločanje vardenafila skozi jetra v primerjavi z zdravimi mlajšimi prostovoljci (18 do 45 let) zmanjšalo.
On average elderly males had a 52% higher AUC, and a 34% higher Cmax than younger males (see section 4.2).
Pri starejših moških je bila AUC za povprečno 52% večja kot pri mlajših moških, Cmax pa za 34% (glejte poglavje 4. 2).
Renal insufficiency In volunteers with mild to moderate renal impairment (creatinine clearance 30 – 80 ml/ min), the pharmacokinetics of vardenafil were similar to that of a normal renal function control group.
Ledvična insuficienca Pri prostovoljcih z blagimi do zmernimi motnjami pri delovanju ledvic (kreatininski očistek 30 do 80 ml/ min) je bila farmakokinetika vardenafila podobna kot pri preiskovancih iz kontrolne
No statistically significant correlation was observed between creatinine clearance and
Pri prostovoljcih z resnimi motnjami pri delovanju ledvic (kreatininski očistek < 30 ml/ min) se je povprečna vrednost AUC zvečala za 21%, povprečna Cmax pa zmanjšala za 23% v primerjavi s prostovoljci brez motenj delovanja ledvic.
11 vardenafil exposure (AUC and Cmax) (see section 4.2).
Med kreatininskim očistkom in izpostavitvijo vardenafilu (AUC in Cmax) niso opazili statistično pomembne korelacije (glejte poglavje 4. 2).
Vardenafil pharmacokinetics has not been studied in patients requiring dialysis (see section 4.3).
Farmakokinetika vardenafila ni raziskana pri bolnikih na dializi (glejte poglavje 4. 3).
Hepatic insufficiency In patients with mild to moderate hepatic impairment (Child-Pugh A and B), the clearance of vardenafil was reduced in proportion to the degree of hepatic impairment.
Jetrna insuficienca Pri bolnikih z blagimi do zmerno hudimi motnjami pri delovanju jeter (A in B po Child- Pughu) se je očistek vardenafila zmanjšal sorazmerno s stopnjo jetrne okvare.
In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects.
22%.
In patients with moderate impairment (Child-Pugh B), the mean AUC and Cmax increased 160% and 133% respectively, compared to healthy control subjects (see section 4.2).
Pri bolnikih z zmernimi motnjami (B po Child- Pughu) sta se povprečni vrednosti AUC in Cmax v primerjavi z zdravimi preiskovanci iz kontrolne skupine zvečali za 160% oz.
The pharmacokinetics of vardenafil in patients with severely impaired hepatic function (Child-Pugh C) has not been studied (see section 4.3).
Farmakokinetika vardenafila pri bolnikih z resnimi motnjami pri delovanju jeter (C po Child- Pughu) ni raziskana (glejte poglavje 4. 3).
Tablet core: crospovidone magnesium stearate microcrystalline cellulose silica, colloidal anhydrous
jedro tablete: krospovidon magnezijev stearat mikrokristalna celuloza brezvoden koloidni silicijev dioksid
Film coat: macrogol 400 hypromellose titanium dioxide (E171) ferric oxide yellow (E172) ferric oxide red (E172)
filmska obloga: makrogol 400 hipromeloza titanov dioksid (E171) rumeni železov oksid (E172) rdeči železov oksid (E172)
PP/ Aluminium foil blisters in cartons of 2, 4, 8 and 12 tablets.
škatla z 2, 4, 8 in 12 tabletami v pretisnem omotu (PP/ aluminij)
6.6 Special precautions for disposal
12 6. 6 Posebni varnostni ukrepi za odstranjevanje
Bayer AG, D-51368 Leverkusen, Germany
Bayer AG, D- 51368 Leverkusen Nemčija
Date of first authorization:
Datum pridobitve dovoljenja za promet:
Levitra 10 mg film-coated tablets
Levitra 10 mg filmsko obložene tablete
Each tablet contains 10 mg of vardenafil (as hydrochloride trihydrate).
Ena tableta vsebuje 10 mg vardenafila v obliki vardenafilijevega klorida trihidrata.
Orange round tablets marked with the BAYER-cross on one side and “ 10 ” on the other side.
Okrogle tablete oranžne barve, na eni strani je oznaka BAYER, na drugi pa številka “ 10 ”.
(see sections 4.3 and 5.2).
Največji priporočen odmerek za bolnike z zmerno jetrno okvaro (B po Child- Pughu) je 10 mg (glejte poglavji 4. 3 in 5. 2).
14 Use in patients with renal impairment
14 Uporaba pri bolnikih z ledvično okvaro
The safety of vardenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated until further information is available:
- ki imajo hude motnje pri delovanju jeter (C po Child- Pughu),
- - -
- ki imajo končno ledvično odpoved, ki zahteva dializno zdravljenje,
severe hepatic impairment (Child-Pugh C), end stage renal disease requiring dialysis, hypotension (blood pressure < 90/ 50 mmHg),
- ki imajo hipotenzijo (krvni tlak < 90/ 50 mmHg),
15 who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
15 Pri bolnikih z anatomsko deformacijo penisa (npr. angulacija (ukrivljenost), kavernozna fibroza ali Peyronijeva bolezen) ali pri bolnikih z boleznimi, zaradi katerih obstaja večja možnost pojava priapizma (npr. anemija srpastih celic, multipli mielom ali levkemija), je treba zdravila za erektilno disfunkcijo uporabljati previdno.
Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see sections 4.5 and 4.2).
Med sočasno uporabo zmernih zaviralcev CYP 3A4 (npr. eritromicin in klaritromicin) je treba odmerek vardenafila po potrebi prilagoditi (glejte poglavji 4. 5 in 4. 2).
16 4.5 Interaction with other medicinal products and other forms of interaction
16 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
In men older than 75 years the concomitant use of vardenafil with itraconazole or ketoconazole is contraindicated (see section 4.3).
Pri moških, starih več kot 75 let, je sočasna uporaba vardenafila in itrakonazola ali ketokonazola kontraindicirana (glejte poglavje 4. 3).
17 Effects of vardenafil on other medicinal products
17 Učinki vardenafila na druga zdravila
4.6 Pregnancy and lactation
18 4. 6 Nosečnost in dojenje
18 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Over 9,500 patients have received Levitra in clinical trials.
Zdravilo Levitra je v kliničnih šreskušanjih jemalo več kot 9500 bolnikov.
Not Known (can not be estimated from available data)
Ni znano (ni mogoče oceniti iz razpoložljivih podatkov)
Nervous System Headache Disorders
Bolezni živčevja
Eye Disorders incl.
zaspanost
Lacrimation increased Visual Disturbance (incl.
sinkopa epileptični napad prehodna popolna amnezija
Intraocular pressure increased
Očesne bolezni vključno s preiskavami
Non-arteritic-anterior ischemic optic neuropathy Visual defects
solzenje motnje vida (tudi ostrine vida) kromatopsija konjunktivitis zamegljen vid
Ear and labyrinth Disorders
zvišan intraokularni tlak
Cardiac Disorders incl. related Investigations
nearteritična anteriorna ishemična optična nevropatija motnje vida
Angina Pectoris Myocardial ischemia
Ušesne bolezni, vključno z motnjami labirinta
Myocardial Infarction
nenadna gluhost **
Respiratory, Thoracic and Mediastinal Disorders
Srčne bolezni vključno s preiskavami
Nasal Congestion
tahikardija palpitacija
Dyspnoea Epistaxis
angina pektoris miokardna ishemija
Laryngeal oedema
miokardni infarkt
Gastrointestinal Disorders incl. related Investigations
Žilne bolezni vključno s preiskavami
Dyspepsia Nausea
rdečica
Abnormal liver function tests GGTP increased
hipertenzija hipotenzija ortostatska hipotenzijah
19 System Organ Class
19 Organski sistem
Skin and Subcutaneous Tissue Disorders
Bolezni dihal, prsnega koša in mediastinalnega prostora
Photosensitivity reaction Face oedema Rash
dispneja epistaksa
Musculoskeletal and Connective Tissue Disorders incl.
Bolezni prebavil vključno s preiskavami
Related Investigations
dispepsija navzea
Blood creatine phosphokinase increased Myalgia Back Pain
nenormalne vrednosti testov jetrnih funkcij zvišana raven GGTP
Muscle Rigidity
Bolezni kože in podkožja
Reproductive System and Breast Disorders
Bolezni mišično - skeletnega sistema in vezivnega tkiva
Priapism Erections increased (prolonged or painful erections)
priapizem podaljšane in boleče erekcije
20 Penile erection is a haemodynamic process.
Erekcija penisa je hemodinamični proces.
The mean maximum decreases in supine systolic blood pressure following 20 mg and 40 mg vardenafil were – 6.9 mmHg under 20 mg and – 4.3 mmHg under 40 mg of vardeanfil, when compared to placebo.
Po zaužitju 20 - in 40- miligramskega odmerka vardenafila je povprečno maksimalno znižanje sistoličnega krvnega tlaka v primerjavi s placebom v ležečem položaju – 6, 9 mmHg po uporabi 20 - miligramskega odmerka) in – 4, 3 mmHg (po uporabi 40- miligramskega odmerka vardenafila).
Both vardenafil and sildenafil showed an increase of Fredericia QTc effect of 4 msec (vardenafil) and 5 msec (sildenafil) when compared to either drug alone.
21 (Fridericia) podaljšala; za 4 msec pri vardenafilu in 5 msec pri sildenafilu v primerjavi s posameznim zdravilom.
The following groups were not well represented in clinical trials: elderly (> 75 years, 2.4%), and patients with
V klinična preskušanja je bilo vključenih le malo starejših bolnikov (> 75 let, 2, 4%) in bolnikov z nekaterimi boleznimi srca in ožilja (glejte poglavje 4. 3).
22 Distribution
Porazdelitev
In volunteers with severe renal impairment (creatinine clearance < 30 ml/ min) the mean AUC was increased by 21% and the mean Cmax decreased by 23%, compared to volunteers with no renal impairment.
Pri prostovoljcih z resnimi motnjami pri delovanju ledvic (kreatininski očistek < 30 ml/ min) se je povprečna vrednost AUC zvečala za 21%, povprečna Cmax pa zmanjšala za 23% v primerjavi s prostovoljci brez motenj delovanja ledvic.
No statistically significant correlation was observed between creatinine clearance and vardenafil exposure (AUC and Cmax) (see section 4.2).
Med kreatininskim očistkom in izpostavitvijo vardenafilu (AUC in Cmax) niso opazili statistično pomembne korelacije (glejte poglavje 4. 2).
23 5.3 Preclinical safety data
5. 3 Predklinični podatki o varnosti
6.6 Special precautions for disposal
24 6. 6 Posebni varnostni ukrepi za odstranjevanje
Levitra 20 mg film-coated tablets
Levitra 20 mg filmsko obložene tablete
Each tablet contains 20 mg of vardenafil (as hydrochloride trihydrate).
Ena tableta vsebuje 20 mg vardenafila v obliki vardenafilijevega klorida trihidrata.
Orange round tablets marked with the BAYER-cross on one side and “ 20 ” on the other side.
Okrogle tablete oranžne barve, na eni strani je znak BAYER, na drugi pa številka “ 20 ”.
26 Use in patients with renal impairment
26 Uporaba pri bolnikih z ledvično okvaro
The safety of vardenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated until further information is available:
Varnost vardenafila ni bila raziskana pri bolnikih,
27 who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
27 Pri bolnikih z anatomsko deformacijo penisa (npr. angulacija (ukrivljenost), kavernozna fibroza ali Peyronijeva bolezen) ali pri bolnikih z boleznimi, zaradi katerih obstaja večja možnost pojava priapizma (npr. anemija srpastih celic, multipli mielom ali levkemija), je treba zdravila za erektilno disfunkcijo uporabljati previdno.
Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see sections 4.5 and 4.2).
Med sočasno uporabo zmernih zaviralcev CYP 3A4 (npr. eritromicin in klaritromicin), je treba odmerek vardenafila po potrebi prilagoditi (glejte poglavji 4. 5 in 4. 2).
28 4.5 Interaction with other medicinal products and other forms of interaction
28 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
29 Effects of vardenafil on other medicinal products
29 Učinki vardenafila na druga zdravila
4.6 Pregnancy and lactation
30 4. 6 Nosečnost in dojenje
30 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Common
Zelo pogosti (≥ 1/ 10)
Common (≥ 1/ 100 and (≥ 1/ 10) < 1/ 10)
Pogosti (≥ 1/ 100 in < 1/ 10)
(≥ 1/ 1,000 and < 1/ 100)*
Občasni (≥ 1/ 1. 000 in < 1/ 100) ∗
(≥ 1/ 10,000 and < 1/ 1,000)*
Redki (≥1/ 10. 000 in < 1/ 1. 000) ∗
(can not be estimated from available data)
Ni znano (ni mogoče oceniti iz razpoložljivih podatkov)
Nervous System Headache Dizziness Disorders
Bolezni živčevja
Somnolence
glavobol
Syncope Seizure Transient global amnesia
vrtoglavica
Vascular Flushing Disorders incl. related Investigations
Srčne bolezni vključno s preiskavami
Hypertension Hypotension Orthostatic Hypotension
tahikardija palpitacija
Respiratory, Nasal Thoracic and Congestion Mediastinal Disorders
angina pektoris miokardna ishemija
Dyspnoea Epistaxis
miokardni infarkt
Laryngeal oedema
Žilne bolezni vključno s preiskavami
Nausea related Investigations
rdečica
31
31 Organski sistem
System Organ
Zelo pogosti (≥ 1/ 10)
Very
Pogosti (≥ 1/ 100 in < 1/ 10)
Common
Občasni (≥ 1/ 1. 000 in < 1/ 100) ∗
Uncommon
Redki (≥1/ 10. 000 in < 1/ 1. 000) ∗
Rare
Bolezni dihal, prsnega koša in mediastinalnega prostora
Not Known
zamašen nos
Class
dispneja epistaksa
Common (≥ 1/ 100 and (≥ 1/ 10) < 1/ 10)
edem larinksa
(≥ 1/ 1,000 and < 1/ 100)*
Bolezni prebavil vključno s preiskavami
(≥ 1/ 10,000 and < 1/ 1,000)*
dispepsija navzea
(can not be estimated from available data)
nenormalne vrednosti testov jetrnih funkcij zvišana raven GGTP
Blood creatine phosphokinase increased Myalgia Back Pain
zvečane vrednosti kreatin fosfokinaze v krvi mialgija bolečine v hrbtu
Muscle Rigidity
mišična rigidnost
32 Penile erection is a haemodynamic process.
Erekcija penisa je hemodinamični proces.
Both vardenafil and sildenafil showed an increase of Fredericia QTc effect of 4 msec (vardenafil) and 5 msec (sildenafil) when compared to either drug alone.
33 (Fridericia) podaljšala; za 4 msec pri vardenafilu in 5 msec pri sildenafilu v primerjavi s posameznim zdravilom.
In a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg.
V klinični študiji pri bolnikih po prostatektomiji, v kateri so primerjali placebo z 10 - in 20 - miligramskimi odmerki vardenafila, je vardenafil pomembno izboljšal erektilno funkcijo, zmožnost doseganja in ohranjanja erekcije (omogočen je bil uspešen spolni odnos), ter otrdelost penisa.
34 Distribution
Porazdelitev
Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins (approximately 95% for vardenafil or M1).
Vardenafil in njegovi glavni presnovek (M1) se obsežno vežeta na plazemske beljakovine (približno 95% vardenafila ali M1).
35 5.3 Preclinical safety data
5. 3 Predklinični podatki o varnosti
6.6 Special precautions for disposal
36 6. 6 Posebni varnostni ukrepi za odstranjevanje
38 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Bayer HealthCare AG D-51368 Leverkusen Germany
Bayer HealthCare AG, D- 51368 Leverkusen, Nemčija
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCTS
• POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Each tablet contains 5 mg vardenafil (as hydrochloride trihydrate).
Ena filmsko obložena tableta vsebuje 5 mg vardenafila v obliki vardenafilijevega klorida trihidrata.
Bayer AG, D-51368 Leverkusen, Germany
Bayer AG, D- 51368 Leverkusen, Nemčija
EU/ 1/ 03/ 248/ 001 2 Tablets EU/ 1/ 03/ 248/ 002 4 Tablets EU/ 1/ 03/ 248/ 003 8 Tablets EU/ 1/ 03/ 248/ 004 12 Tablets
EU/ 1/ 03/ 248/ 001 2 tableti EU/ 1/ 03/ 248/ 002 4 tablete EU/ 1/ 03/ 248/ 003 8 tablet EU/ 1/ 03/ 248/ 004 12 tablet
Each tablet contains 10 mg vardenafil (as hydrochloride trihydrate).
Ena filmsko obložena tableta vsebuje 10 mg vardenafila v obliki vardenafilijevega klorida trihidrata.
EU/ 1/ 03/ 248/ 005 2 Tablets EU/ 1/ 03/ 248/ 006 4 Tablets EU/ 1/ 03/ 248/ 007 8 Tablets EU/ 1/ 03/ 248/ 008 12 Tablets
EU/ 1/ 03/ 248/ 005 2 tableti EU/ 1/ 03/ 248/ 006 4 tablete EU/ 1/ 03/ 248/ 007 8 tablet EU/ 1/ 03/ 248/ 008 12 tablet
Each tablet contains 20 mg vardenafil (as hydrochloride trihydrate).
Ena filmsko obložena tableta vsebuje 20 mg vardenafila v obliki vardenafilijevega klorida trihidrata.
EU/ 1/ 03/ 248/ 009 2 Tablets EU/ 1/ 03/ 248/ 010 4 Tablets EU/ 1/ 03/ 248/ 011 8 Tablets EU/ 1/ 03/ 248/ 012 12 Tablets
EU/ 1/ 03/ 248/ 009 2 tableti EU/ 1/ 03/ 248/ 010 4 tablete EU/ 1/ 03/ 248/ 011 8 tablet EU/ 1/ 03/ 248/ 012 12 tablet
Levitra 5 mg film-coated tablets Vardenafil
Levitra 5 mg filmsko obložene tablete vardenafil
- If any of the side effects gets serious, or you notice any side effects not listed in this leaflet, please
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni
What Levitra is and what it is used for 2.
Kaj je zdravilo Levitra in za kaj ga uporabljamo 2.
Before you take Levitra 3.
Kaj morate vedeti, preden boste vzeli zdravilo Levitra 3.
How to take Levitra 4.
Kako jemati zdravilo Levitra 4.
Possible side effects 5 How to store Levitra 6 Further information
Shranjevanje zdravila Levitra 6.
WHAT LEVITRA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO LEVITRA IN ZA KAJ GA UPORABLJAMO
Levitra belongs to a group of medicines which are used to treat difficulties in getting or keeping an erection (erectile dysfunction).
Levitra spada v skupino zdravil, ki se uporabljajo za zdravljenje težav pri doseganju ali ohranjanju erekcije (erektilne disfunkcije).
At least one in ten men has trouble getting or keeping an erection at some time.
O težavah z erekcijo Najmanj eden od desetih moških ima v določenem obdobju težave z doseganjem ali ohranjanjem erekcije.
How Levitra works
Kako deluje zdravilo Levitra?
LEVITRA allows an erection to last long enough for you to satisfactorily complete sexual activity.
Pomaga vam ohraniti erekcijo toliko časa, da lahko uspešno zaključite spolni odnos.
BEFORE YOU TAKE LEVITRA
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO LEVITRA
Do not take Levitra
Ne jemljite zdravila Levitra
See the
- če ste alergični na (preobčutljivi za) vardenafil ali katerokoli sestavino zdravila Levitra (glejte
ingredients in section 6.
pomožne snovi v poglavju 6).
- If you are taking medicines containing nitrates, such as glycerol trinitrate for angina, or nitric
- če jemljete zdravila, ki vsebujejo nitrate (npr. gliceriltrinitrat za angino pektoris) ali donorje
Taking these medicines with Levitra could seriously affect your blood pressure.
dušikovega oksida (npr. amil nitrit); jemanje teh zdravil skupaj s tabletami Levitra lahko zelo vpliva na vaš krvni tlak
- If you are taking ritonavir or indinavir, medicines for HIV.
- če jemljete ritonavir ali indinavir, zdravili za HIV
- If you are over 75 years of age and are taking ketoconazole or itraconazole, anti-fungal medicines
- če ste stari več kot 75 let in jemljete protiglivični zdravili ketokonazol ali itrakonazol
- If you have a severe heart or liver problem
- če imate resne težave s srcem ali jetri
- If you are having kidney dialysis
- če ste na dializi
- If you have recently had a stroke or heart attack
- če ste pred kratkim doživeli možgansko kap ali srčni napad
- If you have or have had low blood pressure
- če imate ali ste imeli nizek krvni tlak
- If your family has a history of degenerative eye diseases (such as retinitis pigmentosa)
- če je v vaši družinski anamnezi degenerativna bolezen oči (retinitis pigmentosa)
- If you have ever had a condition involving loss of vision due to damage to the optic nerve from
- če ste kadarkoli izgubili vid zaradi poškodbe vidnega živca zaradi nezadostne preskrbe s krvjo,
insufficient blood supply known as non-arteritic ischemic optic neuropathy (NAION)
ki je poznana kot nearteritična anteriorna ishemična optična nevropatija (NAION).